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Abstract
Many health care professionals find it irritating when management gurus recommend solving health care's
problems with approaches they would “copy and paste” from unrelated industries — a former chief executive
of a manufacturing company claims that the same simple lessons that enabled him to transform his own
industry can improve value in health care, or a business-school professor offers an eight-point leadership plan
that she's translated into health care as easily as if she'd translated it into French. Many people who work in
health care value outside perspectives and are open to new approaches — and yet bristle at facile
recommendations emerging from these translations.
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lenge manufacturers of products 
such as energy drinks who have 
determined themselves that caf-
feine is safe at much higher lev-
els, and ultimately regulate the 
amount of caffeine permitted in 
products.
Whether states have authority 
on these issues is an important 
question. Federal law does not 
expressly preempt states from 
making their own determinations 
of GRAS status. However, a state 
taking such an action could place 
itself in conflict with federal law 
and be vulnerable to legal chal-
lenges based on arguments, for 
example, that state actions are 
preempted by federal law. States 
do have authority to use their 
police power to enact regulations 
directed at food-service establish-
ments such as restaurants in or-
der to support public health. 
States could, for example, require 
restaurants to reduce sodium lev-
els in prepared foods, as New 
York City did with trans fat, and 
could require warning labels for 
foods.
Over the past few decades, 
food-safety concerns have expand-
ed from issues of foodborne ill-
ness and contaminants such as 
lead to include the effects food 
ingredients have on chronic dis-
eases such as heart disease. The 
government’s rightful role is to 
continue examining food ingre-
dients to determine safe condi-
tions for their use. The govern-
ment has the authority and 
responsibility to regulate the un-
healthful aspects of the food 
supply, and artificial trans fat is 
likely to be an important fron-
tier. The fact that a regulatory 
arm of the U.S. government is 
now following the lead of other 
countries and some U.S. cities 
and states with regard to trans 
fat suggests that a watershed has 
been reached; regulatory recon-
sideration of ingredients such as 
sugar, caffeine, and salt may well 
be next on the agenda.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
From the Sanford School of Public Policy, 
Duke University, Durham, NC (K.D.B.); and 
the Department of Public Health and the 
Center for Obesity Research and Education, 
Temple University, Philadelphia ( J.L.P.).
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Many health care profession-als find it irritating when 
management gurus recommend 
solving health care’s problems 
with approaches they would 
“copy and paste” from unrelated 
industries — a former chief exec-
utive of a manufacturing com-
pany claims that the same sim-
ple lessons that enabled him to 
transform his own industry can 
improve value in health care, or a 
business-school professor offers 
an eight-point leadership plan 
that she’s translated into health 
care as easily as if she’d trans-
lated it into French. Many people 
who work in health care value 
outside perspectives and are open 
to new approaches — and yet 
bristle at facile recommendations 
emerging from these translations.
At the same time, health care 
improvements can come from 
people who don’t know the field 
asking, genuinely, “Couldn’t you 
do it a different way?” — where 
insiders might be less able to 
imagine alternatives. Principles 
guiding high-impact innovation 
are evolving faster outside health 
care than inside. So it makes 
sense not to give up on the man-
agement gurus entirely, but we 
can distinguish between those 
who follow good innovation prac-
tices and those who don’t. Health 
care is not a single problem but 
thousands of problems, and rath-
er than seeking a solution de-
rived from other fields, we’d do 
better to find a solution process to 
use from within.
The challenge of health care 
innovation lies in combining con-
textual understanding with fresh 
perspectives. We — a physician, 
a business-school professor, a 
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hospital administrator, and an in-
novation executive — have found 
that a four-stage design process 
can produce that combination.1 
The four stages are contextual 
inquiry — immersion in the way 
things currently work; problem 
definition — reexamination of 
the challenge, to ensure that the 
right problem is being solved; di-
vergence — exploration of alter-
natives to the first ideas; and 
rapid validation — moving quick-
ly from prototyping to designing 
of focused experiments testing 
critical assumptions.
This process for high-impact 
innovation can be learned. It is 
informed by models from other 
settings, including the “plan–do–
check–act” cycles credited to 
W. Edwards Deming and the de-
sign approaches of firms such as 
IDEO. The process need not be 
linear, but a willingness to im-
merse oneself in the real context 
as a first step distinguishes the 
external experts who will help 
from those who won’t. For the 
same reason, innovation from 
within has a potential advantage 
in health care settings. Whereas 
in many industries the thought 
leaders are secluded in corporate 
headquarters, physicians and nurs-
es are situated right up front 
with the customers.
And yet as connected as clini-
cians are to their patients, in the 
first phase of the innovation pro-
cess they can do more to embed 
themselves in their patients’ 
lives. For example, we have been 
working to improve medication 
adherence among patients dis-
charged after myocardial infarc-
tion. The ways we gain insight 
about their experience — going 
to their homes and following 
them through their day — are not 
the stuff of everyday physician–
patient encounters, yet they pro-
vide knowledge that’s typically 
not learned in medical school. 
Experiencing the long commute 
without bathroom access that 
keeps someone from taking his 
diuretic exposes the inadequacy 
of better reminders. Noting the 
hand-drawn medication-tracking 
sheet on the refrigerator door of 
a patient now successfully stay-
ing out of the hospital (its size 
legible to a 72-year-old, with 
copies sent to her children) tells 
us something about the design 
and social component of effec-
tive adherence tools. William 
Osler said, “Listen to the patient. 
He is telling you the diagnosis.” 
Clinicians with established rela-
tionships are well positioned to 
get the one step closer required 
for meaningful innovations.
In the second phase, health 
systems too often converge on the 
wrong problem. Pursuing online 
self-scheduling when the need is 
new-patient access may merely 
make it easier to see how long it 
takes to get an appointment. In 
the 1980s, Hertz saw the need to 
address long lines at airport car-
rental locations. Realizing that 
what customers wanted was not 
a shorter line but faster ways to 
get on their way, they were able 
to see past adding agents or 
changing customer paperwork to 
the invention of Hertz Gold, with 
no line at all.
Deliberate divergence, the third 
phase, rarely comes naturally in 
time-starved environments. An-
choring prematurely on a solution 
— perhaps one offered by a ven-
dor promising magic elixirs for 
the pressing need — often results 
in large investments in projects 
that never meet expectations. Al-
ternatively, rapid, lower-cost tests 
of multiple approaches, with ob-
servations about their advantages 
and disadvantages, can lead to 
surprises regarding the nature of 
the problem and what success 
looks like. In recent work on pa-
tient experience, we used a mo-
bile app to elicit real-time patient 
feedback for timely course cor-
rections, but concurrent experi-
ments using pen and paper iden-
tified essential design elements 
that can now be incorporated into 
the more advanced technology.
Commercial entities have em-
braced the fourth phase, design-
ing experiments to test key busi-
ness assumptions in hours or days 
instead of discovering months or 
years later that they invested in 
the wrong strategy. In “vapor 
tests,” retailers sell products they 
haven’t yet created in order to as-
sess demand. “Fake back ends” 
simulate automated solutions be-
fore an organization incurs the 
cost of real automation. Before 
we embarked on complex system 
changes to enable same-day ortho-
pedic scheduling, an enterprising 
practice manager published his 
cell-phone number online to be-
come an experimental call center 
for a 3-day test. This tiny pilot 
told us a lot about how to pro-
ceed and produced impressive 
data that convinced hospital lead-
ership to act. Within health sys-
tems’ many constraints — from 
restrictions on handling of per-
sonal health information to reg-
ulations regarding human-subjects 
research — lie opportunities for 
quick experiments that staff are 
well positioned to conceive and 
execute. The best external experts 
take this approach, but most do 
not evolve big strategies through 
rapid, contextual tests.
Many organizations find it 
easier to spend larger sums on 
outsourced and shrink-wrapped 
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solutions than smaller sums on 
maintaining protected time for 
their staff to drive change. And 
yet clinicians know more than 
outsiders about health care’s cus-
tomers and context; they have 
street credibility and established 
trust relationships in an environ-
ment where those characteristics 
count; they can often reuse expe-
riences in multiple projects; and 
they’re usually mission-driven to 
improve outcomes. They also don’t 
then resell the lessons learned; 
they give them away, in presenta-
tions and papers.
These insiders, however, often 
face three barriers to innovation. 
First, principles of rapid-cycle in-
novation are part of neither med-
ical training nor clinicians’ expe-
rience. Even in academic medical 
centers emphasizing research, 
clinicians who conduct controlled 
experiments in the laboratory of-
ten don’t consider deploying them 
when seeking to improve care 
delivery. But just as operating-
room “timeouts” introduced new 
discipline in clinical settings, 
we’ve seen care teams embrace 
rapid validation methods, testing 
and evaluating new ideas quickly.
Second, insiders’ experience 
can become constraining. Henry 
Ford is often credited with say-
ing that had he asked his cus-
tomers what they wanted, they 
would have said “faster horses.” 
Though he apparently never said 
that, the story highlights the trap 
of envisioning incremental gain 
along established dimensions and 
the difficulty of envisioning the 
kind of change that replaces hors-
es with cars. It’s important to en-
force divergent thinking, in part 
by using analogies when break-
throughs from outside health care 
can expand our vision.
Third, clinicians are busy. 
Health care organizations, oper-
ating on thin margins, rarely al-
low for slack in staff work. Many 
organizations say they simply 
cannot introduce time for step-
ping back and reimagining that 
work: it’s too costly to take the 
workers who add the most value 
off the front lines. But it can be 
done with selected individuals 
and at strategic times. Compa-
nies that have begun insourcing 
innovation couldn’t imagine do-
ing so before they’d designed new 
time-allocation practices. Time 
for engagement is even more crit-
ical in health care: new ideas 
create no value until they’re im-
plemented, and effective imple-
mentation in health care requires 
clinician acceptance.
Forward-thinking health sys-
tems understand the obligation to 
improve value. Health care can 
benefit from outside perspectives 
in this endeavor, but clinicians 
have the requisite drive, experi-
ence, and context to be produc-
tive innovators. If we adapt and 
internalize proven innovation 
principles from other fields, much 
effective innovation can come 
from within.
Disclosure forms provided by the authors 
are available with the full text of this article 
at NEJM.org.
From the Center for Health Equity Research 
and Promotion, Philadelphia Veterans Affairs 
Medical Center (D.A.A.); and the Center for 
Health Care Innovation, Perelman School 
of Medicine (D.A.A., C.T., K.B.M., R.R.), and 
the Mack Institute for Innovation Manage-
ment, the Wharton School (C.T.), University 
of Pennsylvania — all in Philadelphia.
1. Eleven lessons: managing design in eleven 
global brands — a study of the design pro-
cess. London: Design Council, 2007 (https://
www.designcouncil.org.uk/sites/default/files/
asset/document/ElevenLessons_Design 
_Council%20%282%29.pdf).
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FDA Approval of Paroxetine for Menopausal Hot Flushes
Ronald J. Orleans, M.D., Li Li, Ph.D., Myong-Jin Kim, Pharm.D., Jia Guo, Ph.D., Mahboob Sobhan, Ph.D., 
Lisa Soule, M.D., and Hylton V. Joffe, M.D., M.M.Sc.
The recent approval by the Food and Drug Administra-
tion (FDA) of paroxetine (Brisdelle, 
Noven) for the treatment of mod-
erate-to-severe vasomotor symp-
toms associated with meno-
pause was distinctive for at least 
two reasons. First, it offered the 
first nonhormonal option to 
women who cannot or do not 
want to use hormonal medica-
tions to treat their menopausal 
vasomotor symptoms. Second, the 
approval ran counter to the rec-
ommendation of the FDA Repro-
ductive Health Drugs Advisory 
Committee, which had conclud-
ed, by a vote of 10 to 4, that the 
overall benefit–risk profile of 
Brisdelle did not support ap-
proval. The FDA always carefully 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIV OF PENN LIBRARY on July 18, 2017. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
